Indivior shares soar as US judge rules against Dr Reddy

pharmafile | July 16, 2018 | News story | Sales and Marketing  

Shares in the London listed addiction specialist Indivior surged in price today, as the Indian pharmaceutical company Dr Reddy’s Laboratories was blocked from selling generic versions of Indivior’s bestselling opioid addiction treatment, Suboxone Film, in the United States.

Indivior shares plummeted on Wednesday of last week as the company issued a “profit warning” related to the loss of Suboxone Film which generates 80% of the business’ revenue. The company’s shares lost a third of their value as DRL launched a generic version of the company’s central drug.

However, a turnaround came as a court in New Jersey issued a temporary ban on DRL selling or importing its generic sublingual film product in the United States.

Indivior CEO Shaun Thaxter said: “Protecting the integrity of our intellectual property is fundamental to our ability to deliver our vision that all patients around the world have access to evidence-based treatment for addiction and its co-occurring disorders.”

Shares in the Mumbai-listed Dr Reddy’s Laboratories dropped by 9% on the National Stock Exchange of India as the decision blocks the re-launching of their generic product until the patent litigation process is complete.

The launch of the generic threatened a loss of $25 million each year for Indivior as the company lost nearly a billion pounds in market value. While generic versions of Suboxone are available in tablet form, Indivior has pursued a number of legal battles to prevent generic drug makers from flooding the US market.

Louis Goss

Related Content

No items found

Latest content